Infect Chemother.  2017 Sep;49(3):241-242. 10.3947/ic.2017.49.3.241.

Regional Experience of Abacavir: Valuable but Still has Unanswered Question

• Bang JH

• KMID: 2391434
• DOI: http://doi.org/10.3947/ic.2017.49.3.241

Abstract

No abstract available.

MeSH Terms

Dideoxynucleosides
Anti-HIV Agents
Reverse Transcriptase Inhibitors
Dideoxynucleosides
Anti-HIV Agents

Reference

1. AIDS info. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Accessed 12 September, 2017. Available at: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf.

2. Korean Society for AIDS. The 2015 clinical guidelines for the diagnosis and treatment of HIV/AIDS in HIV-infected Koreans. Infect Chemother. 2015; 47:205–211.

3. Ann H, Kim KH, Choi HY, Chang HH, Han SH, Kim KH, Lee JS, Kim YS, Park KH, Kim YK, Sohn JW, Yun NR, Lee CS, Choi YW, Lee YS, Kim SW. Safety and Efficacy of Ziagen (Abacavir Sulfate) in HIV-Infected Korean Patients. Infect Chemother. 2017; 49:205–212.

4. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A. PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008; 358:568–579.

5. D:A:D Study Group. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Møller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008; 371:1417–1426.

6. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, Monforte AD, Friis-Møller N, Kirk O, Fontas E, Weller I, Phillips A, Lundgren J. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010; 201:318–330.

7. Ding X, Andraca-Carrera E, Cooper C, Miele P, Kornegay C, Soukup M, Marcus KA. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr. 2012; 61:441–447.

8. Kurita T, Kitaichi T, Nagao T, Miura T, Kitazono Y. Safety analysis of Ziagen^® (abacavir sulfate) in postmarketing surveillance in Japan. Pharmacoepidemiol Drug Saf. 2014; 23:361–371.

9. Kurita T, Kitaichi T, Nagao T, Miura T, Kitazono Y. Safety analysis of Epzicom^® (lamivudine/abacavir sulfate) in post-marketing surveillance in Japan. Pharmacoepidemiol Drug Saf. 2014; 23:372–381.